Telix Pharmaceuticals Limited
Recent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Semi-annual Revenue
•
in mil. unless spec.Semi-annual Earnings Per Share
•
in mil. unless spec.Semi-annual Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Telix Pharmaceuticals Limited (ASX: TLX), a commercial-stage biopharmaceutical company founded in 2015 and headquartered in Melbourne, Australia, develops and commercializes diagnostic and therapeutic radiopharmaceuticals, or theranostics, focused on precision oncology for urologic (prostate, kidney, bladder), neuro-oncologic (glioma), musculoskeletal (sarcoma), and hematologic cancers. The company operates through Therapeutics, Precision Medicine, Medtech, and Manufacturing Solutions segments, offering products including Illuccix (kit for the preparation of 68Ga-PSMA-11 injection) for PSMA-PET/CT imaging in prostate cancer staging, recurrence detection, and therapy selection; Gozellix (TLX007-CDx), Pixclara (TLX101-CDx), and Zircaix (TLX250-CDx) diagnostic imaging agents for prostate, glioblastoma, and kidney cancers pending U.S. FDA approval in 2025; SENSEI miniature gamma probe for surgical guidance; dosimetry software; AI diagnostic platforms; and an extensive pipeline of late-stage therapeutics such as TLX591 (177Lu-rosopatamab tetraxetan) for castration-resistant prostate cancer in Phase III trials with interim data expected in H1 2025, TLX250 (177Lu-girentuximab) for clear cell renal cell carcinoma, TLX101 (131I-IPA) for glioblastoma, and 90Y-besilesomab for bone marrow conditioning, alongside early-stage alpha-emitters targeting PSMA, CAIX, FAP, LAT, and PDGFR-alpha, plus 153Sm-DOTMP for bone metastases palliation. Telix maintains commercial operations in the United States, Europe (Belgium, Switzerland), Japan, Australia, Canada, and the United Kingdom, with global manufacturing facilities including a major radiopharmaceutical production site opened in Belgium in 2023. Recent developments include the November 2024 announcement to expand its theranostic pipeline with FAP-targeting candidates initially for bladder cancer to complement its urology franchise; the acquisition of IsoTherapeutics in 2024 to bolster U.S. R&D and manufacturing infrastructure; planned pivotal trials in 2025 for Zircaix in renal carcinoma and Pixclara in glioblastoma; and a record presence at EANM 2025 showcasing CAIX and FAP theranostics.
Company News
Telix Reports Third Quarter 2026 Financial Performance
Telix and Ekalia to Collaborate on Astatine-211 Production in the U.S.
Ekalia takes an important step in the deployment of Astatine-211 in the United States through a collaboration agreement with Telix
Profound Medical and Telix Pharmaceuticals Enter Co-Education Agreement to Advance PSMA-Informed Prostate Care
First Patients Dosed with Telix's FDA-Approved Brain Cancer Imaging Drug Pixclara® (floretyrosine F 18)
IBA and Telix strengthen ties through agreement to distribute ARTMS's QIS®
Wall Street Analysts Believe Telix Pharmaceuticals Limited (TLX) Could Rally 83.42%: Here's is How to Trade
Telix Pharmaceuticals (NASDAQ:TLX) Sees Unusually-High Trading Volume – What’s Next?
Telix Pharmaceuticals Limited (TLX) Discusses Strategic Overview and Oncology Pipeline at Research and Development Day Transcript
Telix Pharmaceuticals Limited (TLX) M&A Call Transcript
Telix and ITM Join Forces to Create a Radiopharmaceutical Powerhouse
Australia's Telix Pharma agrees to buy Germany's ITM Isotope for about $1.65 billion
Telix Pharmaceuticals: 'Buy' On Pixclara FDA Approval And TLX591-Tx Part 2 Advancement
Novo Nordisk vs. Regeneron Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
Telix Pharmaceuticals Limited (TLX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
FDA Approves Telix Pharmaceuticals Brain Cancer Imaging Drug
FDA Approves Telix's Brain Cancer Imaging Drug Pixclara
Telix to Present at the Morgan Stanley 24th Annual Global Healthcare Conference and H.C. Wainwright 28th Annual Global Investment Conference
Telix Completes Enrollment in Phase 3 BiPASS Study, Aligns with FDA on NDA Pathway
Telix Appoints David Gill as Chair